Association of GLP1R Polymorphisms With the Incretin Response

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2022 Jun 20

PMID 35723666

Authors

Edgar G Dorsey-Trevino

Varinderpal Kaur

Josep M Mercader

Jose C Florez

Aaron Leong

Affiliations

Soon will be listed here.

Abstract

Context: Polymorphisms in the gene encoding the glucagon-like peptide-1 receptor (GLP1R) are associated with type 2 diabetes but their effects on incretin levels remain unclear.

Objective: We evaluated the physiologic and hormonal effects of GLP1R genotypes before and after interventions that influence glucose physiology.

Design: Pharmacogenetic study conducted at 3 academic centers in Boston, Massachusetts.

Participants: A total of 868 antidiabetic drug-naïve participants with type 2 diabetes or at risk for developing diabetes.

Interventions: We analyzed 5 variants within GLP1R (rs761387, rs10305423, rs10305441, rs742762, and rs10305492) and recorded biochemical data during a 5-mg glipizide challenge and a 75-g oral glucose tolerance test (OGTT) following 4 doses of metformin 500 mg over 2 days.

Main Outcomes: We used an additive mixed-effects model to evaluate the association of these variants with glucose, insulin, and incretin levels over multiple timepoints during the OGTT.

Results: During the OGTT, the G-risk allele at rs761387 was associated with higher total GLP-1 (2.61 pmol/L; 95% CI, 1.0.72-4.50), active GLP-1 (2.61 pmol/L; 95% CI, 0.04-5.18), and a trend toward higher glucose (3.63; 95% CI, -0.16 to 7.42 mg/dL) per allele but was not associated with insulin. During the glipizide challenge, the G allele was associated with higher insulin levels per allele (2.01 IU/mL; 95% CI, 0.26-3.76). The other variants were not associated with any of the outcomes tested.

Conclusions: GLP1R variation is associated with differences in GLP-1 levels following an OGTT load despite no differences in insulin levels, highlighting altered incretin signaling as a potential mechanism by which GLP1R variation affects T2D risk.

Citing Articles

Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women.

Bao X, Liu C, Liu H, Wang Y, Xue P, Li Y J Orthop Surg Res. 2024; 19(1):869.

PMID: 39716293 PMC: 11667832. DOI: 10.1186/s13018-024-05361-z.

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.

Holst J Nat Metab. 2024; 6(10):1866-1885.

PMID: 39160334 DOI: 10.1038/s42255-024-01113-9.

Association between the A316T Mutation and Adolescent Idiopathic Scoliosis in French Canadian and Italian Cohorts.

Normand E, Franco A, Parent S, Lombardi G, Brayda-Bruno M, Colombini A Genes (Basel). 2024; 15(4).

PMID: 38674415 PMC: 11050147. DOI: 10.3390/genes15040481.

Rare Variants of Obesity-Associated Genes in Young Adults with Abdominal Obesity.

Bairqdar A, Shakhtshneider E, Ivanoshchuk D, Mikhailova S, Kashtanova E, Shramko V J Pers Med. 2023; 13(10).

PMID: 37888112 PMC: 10608506. DOI: 10.3390/jpm13101500.

References

Sathananthan A, Dalla Man C, Micheletto F, Zinsmeister A, Camilleri M, Giesler P . Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010; 33(9):2074-6. PMC: 2928367. DOI: 10.2337/dc10-0200. View

Chang C, Chow C, Tellier L, Vattikuti S, Purcell S, Lee J . Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015; 4:7. PMC: 4342193. DOI: 10.1186/s13742-015-0047-8. View

Mulherin A, Oh A, Kim H, Grieco A, Lauffer L, Brubaker P . Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011; 152(12):4610-9. DOI: 10.1210/en.2011-1485. View

Florez J . Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?. Diabetologia. 2017; 60(5):800-807. DOI: 10.1007/s00125-017-4227-1. View

Saxena R, Hivert M, Langenberg C, Tanaka T, Pankow J, Vollenweider P . Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010; 42(2):142-8. PMC: 2922003. DOI: 10.1038/ng.521. View

Fortin J, Schroeder J, Zhu Y, Beinborn M, Kopin A . Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther. 2009; 332(1):274-80. PMC: 2802486. DOI: 10.1124/jpet.109.160531. View

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

Srinivasan S, Kaur V, Chamarthi B, Littleton K, Chen L, Manning A . Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care. 2018; 41(3):554-561. PMC: 5829963. DOI: 10.2337/dc17-1386. View

Cordiner R, Mari A, Tura A, Pearson E . The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin Endocrinol Metab. 2021; 106(7):2036-2046. PMC: 8692237. DOI: 10.1210/clinem/dgab151. View

10.

Pulit S, Stoneman C, Morris A, Wood A, Glastonbury C, Tyrrell J . Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet. 2018; 28(1):166-174. PMC: 6298238. DOI: 10.1093/hmg/ddy327. View

11.

Meier J, Nauck M . Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes. 2010; 59(5):1117-25. PMC: 2857890. DOI: 10.2337/db09-1899. View

12.

Kappe C, Patrone C, Holst J, Zhang Q, Sjoholm A . Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol. 2012; 48(3):322-32. DOI: 10.1007/s00535-012-0637-5. View

13.

Javorsky M, Gotthardova I, Klimcakova L, Kvapil M, Zidzik J, Schroner Z . A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins. Diabetes Obes Metab. 2016; 18(9):941-4. DOI: 10.1111/dom.12682. View

14.

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

15.

McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood A, Teumer A . A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016; 48(10):1279-83. PMC: 5388176. DOI: 10.1038/ng.3643. View

16.

Zhang X, Young R, Bound M, Hu S, Jones K, Horowitz M . Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care. 2019; 42(4):520-528. DOI: 10.2337/dc18-2156. View

17.

Fitipaldi H, McCarthy M, Florez J, Franks P . A Global Overview of Precision Medicine in Type 2 Diabetes. Diabetes. 2018; 67(10):1911-1922. PMC: 6152339. DOI: 10.2337/dbi17-0045. View

18.

Fehmann H, Habener J . Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992; 130(1):159-66. DOI: 10.1210/endo.130.1.1309325. View

19.

Nauck M, Schmidt W, Ebert R, Strietzel J, Cantor P, Hoffmann G . Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab. 1989; 69(3):654-62. DOI: 10.1210/jcem-69-3-654. View

20.

Scrocchi L, Brown T, MacLusky N, Brubaker P, AUERBACH A, Joyner A . Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2(11):1254-8. DOI: 10.1038/nm1196-1254. View